Metabolische Myopathien – Teil II: Störungen des Fett-, Purin- bzw. oxidativen Energiestoffwechsels

Lernziele

Kenntnisse über Ursache, Klinik, Diagnose und Therapie der wichtigsten metabolischen Myopathien bedingt durch Störungen im Bereich des Fett-, Purin- bzw. oxidativen Energiestoffwechsels.

Literatur

• 1 Finsterer J. Metabolische Myopathien – Teil I: Störungen des Kohlehydratstoffwechsels.  Fortschr Neurol Psychiat. 2011;  79 598-606
• 2 DiMauro S, Garone C, Naini A. Metabolic myopathies.  Curr Rheumatol Rep. 2010;  12 386-393
• 3 Hermans M C, Pinto Y M, Merkies I S et al. Hereditary muscular dystrophies and the heart.  Neuromuscul Disord. 2010;  20 479-492
• 4 Dehnert C, Bärtsch P. Diagnostik metabolischer Myopathien.  Dtsch Z Sportmed. 2005;  56 179-180
• 5 Liang W C, Nishino I. State of the art in muscle lipid diseases.  Acta Myol. 2010;  29 351-356
• 6 Laforêt P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges.  Neuromuscul Disord. 2010;  20 693-700
• 7 Spiekerkoetter U, Bastin J, Gillingham M et al. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.  J Inherit Metab Dis. 2010;  33 555-561
• 8 Das A M, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies.  J Biomed Biotechnol. 2010;  2010 340 849
• 9 Kottlors M, Jaksch M, Ketelsen U P et al. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency.  Neuromuscul Disord. 2001;  11 757-759
• 10 Moczulski D, Majak I, Mamczur D. An overview of beta-oxidation disorders.  Postepy Hig Med Dosw. 2009;  63 266-277
• 11 Yamamoto T, Tanaka H, Kobayashi H et al. Retrospective review of Japanese sudden unexpected death in infancy: The importance of metabolic autopsy and expanded newborn screening.  Mol Genet Metab. 2011;  102 399-406
• 12 Bennett M J. Pathophysiology of fatty acid oxidation disorders.  J Inherit Metab Dis. 2010;  33 533-537
• 13 Schulze A, Schmidt C, Kohlmuller D et al. Accurate measurement of free carnitine in dried blood spots by isotope-dilution electrospray tandem mass spectrometry without butylation.  Clin Chim Acta. 2003;  335 137-145
• 14 ter Veld F, Mueller M, Kramer S et al. A novel tandem mass spectrometry method for rapid confirmation of medium- and very long-chain acyl-CoA dehydrogenase deficiency in newborns.  PLoS One. 2009;  4 e6449
• 15 Roe C R, Sweetman L, Roe D S et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.  J Clin Invest. 2002;  110 259-269
• 16 Van Hove J LK, Grunewald S, Jaeken J et al. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD).  Lancet. 2003;  361 1433-1435
• 17 Rinaldo P, Stanley C A, Hsu B YL et al. Sudden neonatal death in carnitine transporter deficiency.  J Pediatr. 1997;  131 304-305
• 18 Rijlaarsdam R S, Spronsen F J, Bink-Boelkens M THE et al. Ventricular fibrillation without overt cardiomyopathy as first presentation of organic cation transporter 2-deficiency in adolescence.  Pacing Clin Electrophysiol. 2004;  27 675-676
• 19 Vijay van S, Patterson A, Olpin S et al. Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants.  J Inherit Metab Dis. 2006;  29 627-630
• 20 Kim S H, Park H D, Sohn Y B et al. Mutations of ACADS Gene Associated with Short-Chain Acyl-Coenzyme A Dehydrogenase Deficiency.  Ann Clin Lab Sci. 2011;  41 84-88
• 21 Frerman F E, Goodman S I. Defects of electron transfer flavoprotein and electron transfer flavoproteinubiquinone oxidoreductase: glutaric acidaemia type II. In: Scriver C R, Beaudet A L, Sly W S, eds. The Metabolic and Molecular Bases of Inherited Disease.. 8th ed. New York: McGraw-Hill; 2001: 2357-2365
• 22 Hug G, Bove K E, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II.  N Engl J Med. 1990;  325 1862-1864
• 23 Bonnefont J P, Demaugre F, Prip-Buus C et al. Carnitine palmitoyltransferase deficiencies.  Mol Genet Metab. 1999;  68 424-440
• 24 Bonnefont J P, Bastin J, Behin A et al. Bezafibrate for an inborn mitochondrial beta-oxidation defect.  N Engl J Med. 2009;  360 838-840
• 25 Roe C R, Yang B Z, Brunengraber H et al. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy.  Neurology. 2008;  71 260-264
• 26 Zia A, Kolodny E H, Pastores G M. Very long chain acyl-CoA dehydrogenase deficiency in a pair of mildly affected monozygotic twin sister in their late fifties.  J Inherit Metab Dis. 2007;  30 817
• 27 Kamijo T, Indo Y, Souri M et al. Medium chain 3-ketoacyl-coenzyme A thiolase deficiency: a new disorder of mitochondrial fatty acid beta-oxidation.  Pediatr Res. 1997;  42 569-576
• 28 Yang S Y, He X Y, Schulz H. 3-Hydroxyacyl-CoA dehydrogenase and short chain 3-hydroxyacyl-CoA dehydrogenase in human health and disease.  FEBS J. 2005;  272 4874-4883
• 29 Finsterer J. Leigh and Leigh-like syndrome in children and adults.  Pediatr Neurol. 2008;  39 223-235
• 30 Finsterer J. Treatment of mitochondrial disorders.  Eur J Paediatr Neurol. 2010;  14 29-44